Skip to main content

Table 2 Demographics, baseline clinical data, and CT scores at baseline and last CT grouped by osteitis severity at last CT

From: Impact of baseline clinical and radiological features on outcome of chronic rhinosinusitis in granulomatosis with polyangiitis

 

No osteitis,

Moderate osteitis,

Severe osteitis,

 

n = 45

n = 34

n = 37

Demographic data

Women; n (%)

23 (51)

15 (44)

15 (41)

Limited GPA, as defined in WGET research group; n (%)

18 (40)

15 (44)

19 (51)

Mean age at diagnosis in years (SD)

44 (20)

54 (18)

39 (18)

Median time in years between symptom onset and diagnosis (range)

44; 0.4 (0.0–9.3)

0.7 (0.0–6.0)

0.4 (0.1–10.0)

 

Missing = 1

  

Median time in years from diagnosis to first CT (range)

0.1 (−3.9–18.5)

0.3 (−2.3–16.1)

0.5 (−1.3–24.6)

Median time in years between first and last CT (range)

4.5 (1.3–12.9)

4.8 (1.1–13.5)

7.3 (2.1–14.7)

Ever smokers; fraction (%)

17/36 (47)

14/30 (47)

17/28 (61)

Mortality; n (%)

3 (7)

3 (9)

4 (11)

Laboratory data

ANCA positive; fraction (%)

44/45 (98)

33/33 (100)

32/32 (100)

ANCA negative; fraction (%)

1/45 (2.2)

0/33 (0)

0/32 (0)

Baseline clinical data, BVAS

General; n (%)

42 (93)

32 (94)

33 (89)

Cutaneous; n (%)

11 (24)

7 (21)

8 (22)

Mucosal membranes/eyes; n (%)

14 (31)

10 (29)

9 (24)

Ear, nose, and throat; n (%)

42 (93)

29 (85)

36 (97)

Bloody nasal discharge/crusts/ulcers/granulomata; n (%)

35 (78)

25 (74)

33 (89)

Paranasal sinus involvement; n (%)

23 (51)

23 (68)

33 (89)

Subglottic stenosis; n (%)

0 (0)

0 (0)

0 (0)

Conductive hearing loss; n (%)

15 (33)

6 (18)

12 (32)

Sensorineural hearing loss; n (%)

5 (11)

1 (3)

1 (3)

Chest; n (%)

26 (58)

21 (62)

22 (59)

Cardiovascular; n (%)

1 (2)

0 (0)

0 (0)

Abdominal; n (%)

3 (7)

1 (3)

2 (5)

Renal; n (%)

27 (60)

20 (59)

15 (41)

Nervous system; n (%)

7 (16)

4 (12)

10 (27)

Surgery at end of follow-up

Sinus surgery; n (%)

1 (2)

4 (12)

17 (46)

CT scores at baseline

Median GOSS (range)

0 (0–0)

2 (0–18)

6 (0–38)

Sinonasal destructions; n (%)

3 (7)

6 (18)

20 (54)

Nasal septum perforation; n (%)

3 (7)

4 (12)

5 (14)

Saddle nose deformity; n (%)

2 (4)

1 (3)

5 (14)

Median LM-score (range)

1 (0–12)

4 (0–22)

9 (0–22)

LM-score >0; n (%)

29 (64)

30 (88)

36 (97)

CT scores at last CT

Median GOSS (range)

0 (0–0)

4 (1–28)

16 (5–49)

Sinonasal destructions; n (%)

6 (13)

11 (32)

33 (89)

Nasal septum perforation; n (%)

6 (13)

7 (21)

13 (35)

Saddle nose deformity; n (%)

2 (4)

4 (12)

10 (27)

Median LM-score (range)

1 (0–7)

4 (0–20)

7 (0–22)

  1. Missing data on ANCA and smoking
  2. Abbreviations:GPA granulomatosis with polyangiitis, WGET Wegener’s Granulomatosis Etanercept Trial, ANCA anti-neutrophil cytoplasmic antibodies, BVAS Birmingham Vasculitis Activity Score, version 3, GOSS Global Osteitis Scoring Scale, LM-score Lund-Mackay score